Mid-weight oncology stocks: The dark horses of cancer research
The oncology industry is vast and has many layers. While big names like Bristol Myers Squibb and Pfizer are dedicating a plethora of resources to defeat cancer, lesser known companies are equally out there trying to treat and prevent the disease. These companies are often involved in within the pharmaceutical and bio industries, with growth stemming from investment and revenues from their various ventures.
This Spark contains some of these middleweight firms involved in cancer research or treatment in the US, with a market cap of between $300m and $2bn. For bigger companies, we have you covered with our other curated list, and we've got your back for the smaller guys too. But don't rely on these lists alone. This isn't advice, so make sure you do your own research.